Oral S-adenosylmethionine in Primary Fibromyalgia. Double-blind Clinical Evaluation

• DOI: 10.3109/03009749109096803
• Publication Date: 2007-11-30T15:05:50Z
• Authors: S. Jacobsen; B. Danneskiold-sa...; R. Bach Andersen
• Keywords: Clinical endpoint; Depression; Morning stiffness

AbstractS-adenosylmethionine is a relatively new anti-inflammatory drug with arjalgesic and antidepressant effects. Efficacy of 800 mg orally administered s-adenosylmethionine daily versus placebo for six weeks was investigated in 44 patients primary fibromyalgia double-blind settings. Tender point score, isokinetic muscle strength, disease activity, subjective symptoms (visual analog scale), mood parameters side effects were evaluated. Improvements seen clinical activity (P=0.04), pain experienced during the last week (P=0.002), fatigue (P=0.02), morning stiffness (P=0.03) evaluated by Face Scale (P=0.006) actively treated group compared to placebo. The tender Beck Depression Inventory did not differ two treatment groups. S-adenosylmethionine has some beneficial on could be an important option hereof.Key Words: Fibromyalgias-adenosylmethioninemanagementtender pointsisokinetic strengthdisease